Siemens Healthineers Ag · XETR:SHL

Siemens Healthineers — Q1 FY2025 Earnings Presentation

21 slides from Siemens Healthineers's earnings presentation, Feb 6, 2025

  1. Slide 1: Q1 Analyst Call

    Q1 Analyst Call Bernd Montag, CEO | Jochen Schmitz, CFO February 06, 2025

  2. Slide 2: Safe Harbour Statement

    Safe Harbour Statement This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be

  3. Slide 3: Successful start to FY2025

    Successful start to FY2025 • Revenue growth at 5.7% ─ well within full-year guidance range • Adj. basic EPS at €0.51 ─ driven by y-o-y margin expansion • Outlook confirmed • Equipment book-to-bill of 1.21, broad based across businesses and markets • Imaging growth at 8%, margin at 18.7%, held back y

  4. Slide 4: Successful start to FY2025

    Successful start to FY2025 Revenue (€m) Adjusted basic earnings per share (€) Comparable PYQ: +5.7% PYQ: +4% Y-o-y Growth +5.7% -2% Ex antigen +7.0% Ex antigen +5% 5,176 5,482 0.49 0.51 Q1 FY2024 Q1 FY2025 Q1 FY2024 Q1 FY2025 • Revenue growth of 6% on tough comps (PYQ: 7% ex antigen) • Adj. EBIT inc

  5. Slide 5: Imaging – strong start to the fiscal year

    Imaging – strong start to the fiscal year Leveraging the power of our unique, Imaging (€m) synergistic portfolio and capabilities Revenue Adj. EBIT (margin) Winning together Comparable +7.6% Margin -40 bps Growth Y-o-y 533 565 2,792 3,013 (19.1%) (18.7%) Q1 FY2024 Q1 FY2025 Q1 FY2024 Q1 FY2025 • Rev

  6. Slide 6: Varian and Advanced Therapies – strong growth and solid start

    Varian – strong growth and margin expansion Advanced Therapies – solid start to the fiscal year Varian (€m) Advanced Therapies (€m) Revenue Adj. EBIT (margin) Revenue Adj. EBIT (margin) Comparable Margin Comparable Margin Growth +6.2% Y-o-y +120 bps Growth +5.1% Y-o-y -20 bps 145 166 68 70 911 974 4

  7. Slide 7: Diagnostics – transformation well on track

    Diagnostics – transformation well on track Crystalizing full potential of Diagnostics (€m) growth and profitability Revenue Adj. EBIT (margin) Transforming to win Comparable +1.6% Margin +270 bps Growth Y-o-y 83 54 (7.8%) 1,058 1,068 (5.1%) Q1 FY2024 Q1 FY2025 Q1 FY2024 Q1 FY2025 • Continued revenue

  8. Slide 8: Consistent revenue and margin expansion continues in 2025

    Consistent revenue and margin expansion continues in 2025 Revenue and margin by quarter for FY23, FY24 and FY25(E) FY23 FY24 17.7% FY25 FY25E Adj. EBIT 17.2% margin FY25E 15.2% 15.0% 15.1% 6.3 14.3% 14.6% 6.1 14.3% 13.5% 5.5 5.4 5.4 Revenue 5.3 (€bn) 5.2 5.2 5.1 Q1 Q2 Q3 Q4 Note: FY25E for illustrat

  9. Slide 9: RSNA 2024: Innovation leadership widened… again!

    RSNA 2024: Innovation leadership widened… again! Magnetom Flow. 1.5 Tesla DryCool technology MRI with increased patient comfort: 70 cm BIOGRAPH One 38,000+ attendees PET/MR to support theranostics SOMATOM On.site Bringing critical care imaging to the patient World’s first fleet of photon-counting CT

  10. Slide 10: Revolutionizing the clinical relevance of CT with Photon Counting

    Revolutionizing the clinical relevance of CT with Photon Counting Cardiovascular diseases Cancer Neurovascular diseases Coronary artery disease: Evaluate plaque and Pancreatic cancer: Visualization with clearer Small aneurysms: Benchmark in Ultra High- stent patency reliably; potential to reduce cos

  11. Slide 11: Addressing important workflow challenges with key innovations

    Addressing important workflow challenges with key innovations Magnetom Flow. 1.5 Tesla – manifesting our leadership in MRI Significantly Improving ease reduced scanning Delivering of use, tackling time and higher significant energy workforce resolution savings shortage • Elevated patient comfort • E

  12. Slide 12: Leading position in the field of Theranostics further strengthened

    Leading position in the field of Theranostics further strengthened Expanding global footprint Driving clinical advancements in Theranostics with the broadest portfolio at control point of tracer production and distribution • Successful closing of acquisition of radiopharmaceuticals business PETNET S

  13. Slide 13: Increasing our order backlog with Value Partnerships and large deals

    Increasing our order backlog with Value Partnerships and large deals – driving long-term growth Global expansion of Value Partnerships Strong performance also in Q1 2025 >€5bn order backlog • Continued strong order intake from Value Partnerships and large deals contributed to excellent equipment boo

  14. Slide 14: Outlook FY2025 confirmed

    Outlook FY2025 confirmed FY2024 FY2025E Revenue growth1 5.2% Revenue growth 5 to 6% Adj. EPS €2.23 Adj. EPS €2.35 to 2.50 1 Excluding antigen of €121m in FY2023; FY2024 and FY2025 include no antigen Q1 FY2025 Note: Outlook for FY2025 is based on assumptions on macroeconomic environment, interest rat

  15. Slide 15: Appendix

    Appendix Q1 FY2025 Unrestricted © Siemens Healthineers AG, 2025 l 15

  16. Slide 16: EBIT to Free Cash Flow Bridge Q1 FY25

    EBIT to Free Cash Flow Bridge Q1 FY25 Q1 FY25 Siemens Healthineers EBIT to Free Cash Flow (€m) Imaging 1.0 CCR2 Diagnostics <0 Varian 1.4 Adv. Therapies 1.4 CCR1 0.88 1″003 155′ -230′ 911′ 789′ 213′ -88′ 71′ 69′ 810′ 698′ 49′ 91′ 692′ -170′ -49′ Healthineers PPA EBIT excl. Depr. of PPE EBITDA Change

  17. Slide 17: FY25 balance sheet and net debt bridge

    FY25 balance sheet and net debt bridge Net debt overview Capital structure development in FY25 (in €bn) in €bn Sep 30, 2024 Dec 31, 2024 Leverage1 3.3x 3.1x Cash and cash equivalents 2.7 2.8 13.2 13.0 Receivables from the Siemens Pensions 0.6 0.6 0.0 0.1 Group from financing activities -1.0 0.4 0.4

  18. Slide 18: Loan maturity profile

    Loan maturity profile Loans with Siemens Group as of Dec 31st, 2024 (in €m) Comments EUR ▪ Total loan volume ~€13.9bn equivalent USD hedged in EUR ▪ Average interest rate ~2.1% p.a.3 USD Top 10 loans ranked in € volume Others Notional Volume Volume Interest 1,756 Maturity Currency in m in €m rate 1,

  19. Slide 19: Provisions for pensions

    Provisions for pensions Q1 FY2025 Key financials – Pensions and similar obligations Q1 in €bn1 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 Defined benefit (3.4) (3.8) (3.8) (4.1) (3.3) (3.2) (3.5) (3.5) obligation (DBO) Fair value of 2.6 2.8 2.8 3.3 2.8 2.8 3.0 3.1 plan assets Provisions

  20. Slide 20: Glossary

    Glossary ‘Revenue’ in this presentation refers for segments to ‘Adjusted revenue‘ Adjusted revenue is defined as consolidated revenue reported in the company’s consolidated statements of income adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocatio

  21. Slide 21: Q1 FY2025 Unrestricted © Siemens Healthineers AG, 2025 l 21

    Q1 FY2025 Unrestricted © Siemens Healthineers AG, 2025 l 21

Siemens Healthineers — Q1 FY2025 Earnings Presentation on 6ix